Navigation Links
Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
Date:10/22/2007

Dr. Rene Bruno Will Present on the Value of Clinical Trial Simulations to

Predict Efficacy and Survival Benefit of Anticancer Agents

MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe, has been invited to speak to academics, regulators, and members of the Chinese pharmaceutical industry attending the International Symposium in Quantitative Pharmacology in Drug Development and Regulation. The symposium will be held in Nanjing China at the International Conference Hotel from October 29-31, 2007.

Dr. Bruno will join other leading experts from industry, government and academia in a scientific program that will discuss the latest methodologies in pharmacometrics, focusing on pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation in drug development, regulation and clinical applications. The symposium will also provide a forum for scientific discussion and collaborative exchange on model-based approaches in drug development. Dr. Bruno's presentation, discussing a model-based approach to support drug development in oncology, will be part of a session focusing on the theory and applications of model-based drug development. The presentation, entitled "Clinical Trial Simulations to Predict Efficacy and Survival Benefit of Anticancer Agents", will take place on October 29, 2007. Dr. Bruno also serves on the symposium's international advisory committee.

"Model-based drug development continues to grow as a value-added method for optimizing decisions in the drug development process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development is benefiting from the quantitative application of drug-disease models to simulate expected clinical re
'/>"/>

SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Why companies dont get invited to the DEMO conference
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... DUBLIN , Aug. 22, 2014 ... the "Global and China Gel Permeation Chromatography (GPC) ... The Global and China Gel Permeation Chromatography ... on the current state of the global gel permeation ... The report provides a basic overview of the ...
(Date:8/22/2014)... 22, 2014 The AMA is pleased ... members in Alaska that Alaska Governor Sean Parnell has ... further defining public use of Unmanned Aircraft Systems and ... House Bill 255states that it is, “An Act relating ... by an unmanned aircraft system.” It defines State of ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
Breaking Biology Technology:Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2State of Alaska Signs Unmanned Aircraft Systems Bill 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... General Meeting Summary: Genmab to hold Annual ... 7 Genmab A/S (OMX:,GEN) summon the Annual General Meeting ... Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300,Copenhagen S, Denmark., ... on the Company,s activities during,the year., 2. Presentation of ...
... Mo. A modern computer contains two different types ... semiconductor components, which perform logic operations. A University of ... is working to combine these two functions in a ... integration of memory and logical functions and is expected ...
... (NASDAQ: ANPI , TSX: ANP), a global ... the first New Zealand patient,was treated with Cook ... 2007. A second patient was treated in February,2008. ... stent for peripheral,arterial disease (PAD) and was recently ...
Cached Biology Technology:Genmab A/S - Notice to Convene Annual General Meeting 2Genmab A/S - Notice to Convene Annual General Meeting 3Genmab A/S - Notice to Convene Annual General Meeting 4Genmab A/S - Notice to Convene Annual General Meeting 5Genmab A/S - Notice to Convene Annual General Meeting 6Genmab A/S - Notice to Convene Annual General Meeting 7Hybrid computer materials may lead to faster, cheaper technology 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4
(Date:8/21/2014)... consists of radiations in the 3.3 to 4.4 nanometre ... biological tissues. New theoretical findings show that it is ... These could be the basis of an optimal technique ... or to be used in high-precision spectroscopy. Now, a ... efficiently generate the harmonic radiationswhich are multiples of an ...
(Date:8/21/2014)... connectors, designed by an international standards process, will be ... to an invited review published in the OnlineFirst version ... ), the official journal of the American Society for ... greatly reduce the occurrence of misconnection that can be ... which are used to join medical devices, components, and ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... BIRMINGHAM, Ala. Scientists have pinpointed a set of ... risk for lupus in women who carry them. Some ... lupus patients, which may help future studies examining whether ... groups, according to a new study. Also, the ...
... release is available in French . , ... that small differences between individuals at the DNA level ... produce proteins. These, in turn, are responsible for the ... The study, part of the Genome Regulators in Disease ...
... at Cardiff University have made a breakthrough in breast ... women who become resistant to breast cancer drugs such ... been a huge success in treating breast cancer, for ... to work, or after an initial successful response the ...
Cached Biology News:DNA variations signal lupus risk 2DNA variations signal lupus risk 3Tiny genetic differences have huge consequences: McGill researchers 2Further breakthroughs for breast cancer patients 2
Human Glypican 2 Biotinylated Affinity Purified PAb...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Biology Products: